Japanese big pharma Eisai taps Celgene and Sanofi execs as its new VPs for corporate affairs and market access. And Freeline Therapeutics, developer of gene therapies for bleeding disorders, selects a former Alnylam Pharma SVP as CEO.

Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.

Takeda Vaccines VP switches to cancer immunotherapy and vaccine company Bavarian Nordic and Novartis Institutes exec moves to molecular medicines firm Boston Pharmaceuticals, each in the CMO position. Meanwhile, Merck & Co will add a scientific and a strategic expert to its board.

Stryker tech officer will become Bayer AG’s chief information technology and digital transformation Officer in June. In addition, monoclonal antibody therapy firm CytoDyn and global pharma Eli Lilly each hire a general counsel.

Syncona-backed Freeline has nabbed an "accomplished commercial leader" in Theresa Heggie to lead the company as it prepares to take FLT180a, its gene therapy for hemophilia B, into Phase III.

Ex-Torrent COO Arunesh Verma to lead Cipla’s North America generics business, while the head of Cipla USA has been repositioned to lead the India prescription business, among other personnel changes.

Cellular and immune therapeutics company Gamida Cell has a new chief regulatory and quality officer and the SVP, R&D at Twist Biosciences steps higher to the chief operating officer position. At Sanofi Genzyme a genetic diseases VP leaves to become chief commercial officer at Krystal Biotech.

Hilleman CEO Davinder Gill is leaving the global vaccine R&D organization after eight years at the helm and several mileposts. Incoming CEO Raman Rao takes charge from 1 February.

Gene-editing company Editas Medicine appoints a new CFO, while Affimed and NexImmune bring new chief medical officers on board.

A Roche director joins predictive drug discovery firm Compugen and a Bristol-Myers Squibb exec is welcomed at immuno-oncology company Turnstone Biologics – both in Business Development. And China- and US-based biopharma Antegene brings on Celgene manager as CBO.

The CEO of Ipsen Group departs to take top job at new gene therapy company FerGene and Novo Nordisk’s VP, regulatory affairs moves to EVP, quality and regulatory at Scandinavian orthobiologics firm BoneSupport. At commercial-stage pharma business PDL BioPharma, a chairperson is elected.

New CEOs for Abgenomics, Advangen, Dynavax Technologies, Merus and Nuvelution are among the latest biopharma appointments. Kiadis Pharma’s CFO’s resignation takes effect on 31 December.